<DOC>
	<DOCNO>NCT01234649</DOCNO>
	<brief_summary>A diagnosis gestational diabetes mellitus ( GDM ) significant implication future health mother . GDM often culmination year unrecognized unmodified diabetes risk factor lead overt occult clinical manifestation pregnancy . Systematic review old study conclude 35-60 % woman gestational diabetes develop type 2 diabetes ( DM2 ) rate much great control group glucose intolerance pregnancy . Liraglutide may potentially delay disease progression GDM consider beta - ( ß- ) cell function improvement DM2 ß-cell mass show increase animal model . This study examine addition liraglutide metformin therapy effective metformin alone improve insulin sensitivity normalize insulin secretion at-risk overweight/obese woman prior GDM .</brief_summary>
	<brief_title>Combined Liraglutide Metformin Therapy Women With Previous Gestational Diabetes Mellitus ( GDM )</brief_title>
	<detailed_description>Gestational diabetes often culmination year unrecognized unmodified diabetes risk factor lead overt occult clinical manifestation pregnancy . . Despite high increase rate type 2 diabetes Louisiana , medical community reliable estimate number woman live southern Louisiana develop diabetes subsequent GDM . Systematic review old study conclude 35-60 % woman gestational diabetes develop type 2 diabetes rate much great control group glucose intolerance pregnancy . The high rate study particular ethnic group U.S . Recently , follow-up program elsewhere also identify increase rate type 2 diabetes 5-10 year GDM : 9-43 % type 2 diabetes Europe 11-21 % Asia . The frequency type 2 diabetes influence BMI , weight gain pregnancy , family history diabetes , fast postchallenge glucose level pregnancy , postpartum insulin resistance inadequate β-cell secretion , need pharmacological treatment pregnancy . However , risk factor unable predict case subsequent type 2 diabetes : big risk factor GDM pregnancy . Presently , literature , describe new , efficient method diabetes prevention group high risk disorder , involve , lifestyle modification pharmacological therapy . Lifestyle intervention find reduce incidence type 2 diabetes 58 % metformin 31 % compare placebo . The use rosiglitazone subject prediabetes result 60 % reduction diabetes incidence rate . Studies need optimal postpartum long-term health woman GDM . Considerable recent evidence suggest incretin-based therapy may useful treatment DM2 continuous administration glucagon-like peptide 1 ( GLP-1 ) produce substantial improvement glucose control ß-cell function subject type 2 diabetes . Infusion GLP-1 improve first second-phase insulin secretion suggest early GLP-1 therapy may preserve ß-cell function subject IGT mild DM2 . Whereas native GLP-1 short half-life , GLP-1 analogue liraglutide prolong action ( t1/2=13 h ) suitable once-daily injection . Liraglutide may potentially delay disease progression GDM consider ß-cell function improvement DM2 ß-cell mass show increase animal model . This study examine addition liraglutide metformin therapy effective metformin alone improve metabolic parameter at-risk overweight/obese woman prior GDM</detailed_description>
	<mesh_term>Diabetes Mellitus</mesh_term>
	<mesh_term>Diabetes Mellitus , Type 2</mesh_term>
	<mesh_term>Metabolic Syndrome X</mesh_term>
	<mesh_term>Diabetes , Gestational</mesh_term>
	<mesh_term>Glucose Intolerance</mesh_term>
	<mesh_term>Metformin</mesh_term>
	<mesh_term>Liraglutide</mesh_term>
	<mesh_term>Glucagon-Like Peptide 1</mesh_term>
	<criteria>Adult female 18 year 45 year age experience GDM within 52 week index pregnancy Actual BMI &gt; 25 kg/ m2 Written consent participation study Patient complete lactation Dysglycemia ( impaired fasting glucose [ IFG } , impair glucose tolerance [ IGT } IFG/IGT ) and/or ßcell dysfunction postpartum require pharmacological intervention ( except type 1 2 diabetes ) Personal family history medullary thyroid carcinoma patient Multiple Endocrine Neoplasia syndrome type 2 History pancreatitis Significant cardiovascular , cerebrovascular , renal , hepatobiliary disease past ( viral hepatitis , toxic hepatic damage , jaundice unknown etiology ) Serum liver enzyme ( AST and/or ALT level ) exceed twice normal laboratory value Uncontrolled hypertension ( systolic blood pressure &gt; 150 mm Hg and/or diastolic blood pressure &gt; 90 mm Hg ) Fasting serum triglyceride ≥800 mg/dl screening . Lipidlowering medication must maintain dose 3 month prior enrollment Hematological profile consider clinically significant Cholestasis past pregnancy Presence contradiction GLP1 receptor agonist metformin administration allergy hypersensitivity Current use metformin , thiazolidinediones , dipeptidyl peptidase4 inhibitor GLP1 receptor agonist medication . Use drug know exacerbate glucose tolerance . Use prescription overthecounter weightloss drug Diabetes postpartum history diabetes prior use medication treat diabetes except gestational diabetes Creatinine clearance le 60 ml/min History currently undergo chemotherapy radiotherapy cancer Pregnancy plan come two year Currently breastfeed Exclusion criterion include condition , opinion investigator would place subject increase risk otherwise make subject unsuitable participation study</criteria>
	<gender>Female</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>45 Years</maximum_age>
	<verification_date>June 2016</verification_date>
	<keyword>gestational diabetes mellitus</keyword>
	<keyword>type 2 diabetes mellitus</keyword>
	<keyword>metabolic dysfunction</keyword>
	<keyword>impaired fasting glucose</keyword>
	<keyword>impaired glucose tolerance</keyword>
	<keyword>incretin mimetic</keyword>
</DOC>